Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Back to alerts
BSEZENITH HEALTH CARE LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 14 Jul, 2026 · 21:44 IST

Board approves amalgamation with group firm Achyut Healthcare

Nclt Scheme FiledStrategic Transactions View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+8.9%Reaction day
₹3.05
prior close
₹3.11
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+8.2% vs market
Pharmaceuticals peers, median of 165sector+0.0%+8.8% vs sector

On the reaction day the stock moved 8.2 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+4.5
10m
+5.8
15m
+3.9
30m
+3.9
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+8.9+0.6+8.2+0.0+8.8
Next day
+9.2+0.2+9.0+0.0+9.2
2d
+7.2-0.9+8.1-1.1+8.3
3d
+12.5-0.3+12.8-0.5+13.0
4d
+14.8+0.0+14.7-0.4+15.1
5d
+10.8-1.1+12.0-1.7+12.5
1w
+6.9-1.4+8.3-2.6+9.5
15d
+4.6+2.7+1.9-1.2+5.8
1m
+1.0+3.6-2.6-0.5+1.4
2m
+7.2+2.0+5.2-0.6+7.8
3m
+3.0+1.1+1.9-2.3+5.3
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zenith Healthcare board approved amalgamation of Achyut Healthcare (same group) into itself. Exchange ratio: 119 Zenith shares for every 50 Achyut shares. No cash consideration. Achyut FY26 turnover Rs 1197 lakh, assets Rs 3809 lakh. Scheme subject to NCLT and shareholder approvals. Post-merger Zenith promoter stake rises from 28.74% to 45.80% as new shares are issued to Achyut shareholders.

Likely market impact

Expands pharma portfolio and capacity. New equity issuance will significantly dilute existing public shareholders. Awaiting NCLT and shareholder approval.